Servier's VORANIGO® Shows Promising Long-Term Benefits in Extended INDIGO Trial Results

Exciting Developments in Glioma Treatment: VORANIGO®'s Extended Trial Results

Servier Pharmaceuticals has made a significant announcement regarding the extended results from the Phase 3 INDIGO trial assessing VORANIGO® (vorasidenib). At the American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026, groundbreaking data was shared about the efficacy and safety of VORANIGO in treating Grade 2 IDH-mutant glioma.

The trial followed patients undergoing treatment for more than three years, with an emphasis on evaluating the durability and sustained benefits of VORANIGO. Results indicated an impressive median progression-free survival of 44.1 months among the participants treated with VORANIGO, a critical metric denoting the length of time patients lived without their cancer progressing. This data reinforces the findings from the initial INDIGO pivotal trial and showcases the drug’s long-term benefits for glioma patients.

The extended analysis incorporated 21.3 months of additional unblinded data gathered after the trial’s initial unblinding in March 2023. The results highlighted that all patients from the placebo arm had eventually transitioned to the VORANIGO treatment, showcasing the trial's compelling nature.

Dr. Islam Hassan, Global Head of Development-Neuro-Oncology at Servier, noted that the extended analysis significantly enhances the understanding of VORANIGO’s clinical advantages. He stated, “With more than three years of follow-up data, these results validate the durable and sustained benefits of long-term treatment with VORANIGO.” It emphasizes a continual improvement in patient responses even after substantial time frames, indicating that the treatment not only combats the disease but also enhances patient quality of life.

In the INDIGO trial, findings presented by Dr. Timothy Cloughesy from UCLA revealed that VORANIGO treatment helped delay the need for subsequent interventions in 23.8% of patients, alongside exhibiting an objective response rate of 20.8%. These numbers reflect a strong correlation between long-term therapy with VORANIGO and improved patient outcomes.

Moreover, a notable reduction in on-treatment seizures—by 72%—was reported among those treated with VORANIGO, emphasizing its efficacy not just in staving off disease progression but also in enhancing the overall well-being of patients.

The safety profile of VORANIGO remained consistent with previous findings, characterized primarily by low-grade adverse events. Importantly, no new safety signals emerged, ensuring confidence in the drug's ongoing use. The most common treatment-related adverse events reported were manageable and did not result in treatment discontinuation for most participants.

Prior to this study, patients with Grade 2 IDH-mutant gliomas struggled with poor prognoses, often resorting to a 'watch and wait' approach due to the limited available treatments. The insights gained from Servier's Phase 3 INDIGO trial paint a brighter picture for these patients, providing critical data about the potential of VORANIGO to not only extend survival but also enhance life quality.

Furthermore, the ASCO meeting will also highlight a separate exploratory analysis focusing on the impact of VORANIGO on seizure rates and quality of life. Preliminary data suggests a sustained positive effect on seizure management, particularly notable for patients with oligodendrogliomas.

Servier's commitment to oncology is backed by significant investments in research and development, underscoring their mission to push boundaries in cancer treatment. They continue to work towards providing targeted therapy options that can cater specifically to the needs of patients battling glioma, enriching the oncology landscape.

In summary, the extended follow-up results from the INDIGO trial are not just numbers; they represent hope for glioma patients. With VORANIGO® showing promising results in terms of progression-free survival and overall patient well-being, the future looks more promising for individuals facing these challenging diagnoses.